Lyell Immunopharma Inc., a clinical-stage company focused on CAR T-cell therapies, has announced new management appointments to strengthen its clinical and commercial capabilities. Mark J. Bachleda, PharmD, MBA, has been appointed as an independent member of the Board of Directors. Additionally, David Shook, MD, has been named Chief Medical Officer, Mark Meltz, JD, as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA, as Senior Vice-President of Medical Affairs. These changes come as Lyell advances its programs for LYL314, targeting aggressive large B-cell lymphoma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.